Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17542448 | 0.84 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL1190095 | 0.80 | CYP3A4 (0.50) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL70939 | 0.77 | NPSR1 (0.54) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL8942099 | 0.76 | NPSR1 (0.49) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL69083 | 0.76 | OPRM1 (0.56) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL1368994 | 0.75 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL1190457 | 0.75 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL21133718 | 0.73 | OPRM1 (0.32) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL5459825 | 0.73 | OPRM1 (0.47) | OPRM1OPRD1OPRK1OPRL1NPSR1 | |
| SCHEMBL17049270 | 0.73 | OPRM1 (0.56) | OPRM1OPRD1OPRK1OPRL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3575299-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-12-04 | — | — | EP | disclosed |
| EP-3575299-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-12-04 | — | — | EP | disclosed |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3110816-B1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902721-B2 | N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-12-15 | — | — | US | disclosed |
| WO-2015128676-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015128676-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | WO | disclosed |
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | OPRM1 383/4885OPRD1 83/4885OPRK1 505/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | OPRM1 376/4885OPRD1 94/4885OPRK1 547/4885 |
| US-20160362409-A1 | N2-PHENYL-PYRIDO[3,4-D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | OPRM1 4708/4885OPRD1 4465/4885OPRK1 3833/4885 |
| US-20180194761-A1 | N2-PHENYL-PYRIDO[3,4- D]PYRIMIDINE-2, 8-DIAMINE DERIVATIVES AND THEIR USE AS MPS1 INHIBITORS | BUB1, BUB1B, CDK1 | OPRM1 4708/4885OPRD1 4465/4885OPRK1 3833/4885 |
| US-10399974-B2 | N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors | BUB1, BUB1B, CDK1 | OPRM1 4708/4885OPRD1 4465/4885OPRK1 3833/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | OPRM1 844/4885OPRD1 261/4885OPRK1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.